We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Factors Limiting Diversity in Cancer Research

Factors Limiting Diversity in Cancer Research content piece image
Credit: Pavel Danilyuk/ Pexels
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

A commentary by researchers from Mayo Clinic and the University of Southern California suggests that agencies funding biomedical research must strive for diversity, equity and inclusion in research decisions, and that these agencies will only be successful if they address bias in the research funding process. The commentary is published in Nature Medicine.

"The lack of diversity in science and medicine exacerbates and compounds the problem of health disparities," says Folakemi Odedina, Ph.D., a Mayo Clinic cancer researcher. Dr. Odedina's education, training and community outreach activities have focused on addressing health disparities in racial, ethnic minority and underserved communities.

Dr. Odedina and co-author Mariana Stern, Ph.D., of the University of Southern California write that the relatively small number of minority clinicians and researchers in biomedical research in the U.S., and the lack of minority participants in clinical trials, poses significant barriers to addressing health disparities. For example, "Black investigators continue to be underfunded in science and medicine due to bias in the scientific review process," says Dr. Odedina. She says multiple reasons have been associated with this bias, including a perception that Black investigators are less capable or less accomplished than White or Asian candidates.

The authors say another factor limiting diversity in biomedical research is a misalignment between the priorities of funding agencies and the research focus of scientists from underrepresented groups. "Funding decisions that do not appropriately weigh the potential impact of awards on minority communities or the importance of promoting the careers of diverse scientists ― Black, Latinx and Indigenous ― miss the opportunity to improve diversity, equity and inclusion in science and medicine, and improve the health of minority communities," says Dr. Odedina.

Dr. Odedina says funding organizations can play a critical role in addressing diversity and equity issues in medical research. "They can start by addressing diversity among their own staffs by prioritizing health disparities research when developing funding opportunities and by making funding decisions that address health disparities and promote scientists from underrepresented groups."

Dr. Odedina says bias toward Black scientists in academic funding has led many to switch to academic administrative positions or to leave academia altogether, as it is very difficult to be successful without extramural funding. "In the U.S., there is a nationwide problem retaining Black scientists in academia," says Dr. Odedina. She says the downstream effect of this problem is fewer Black scientists in academia and biomedical research, as the pipeline continues to decrease.

Dr. Odedina says that efforts to ensure a well-trained, racially and ethnically diverse workforce in science and medicine will effectively and respectfully help deliver health care interventions for diverse populations and help eliminate health disparities.

Reference: Odedina FT, Stern MC. Role of funders in addressing the continued lack of diversity in science and medicine. Nat Med. 2021:1-3. doi: 10.1038/s41591-021-01555-8

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.